Resmed (RMD) announced the publication of a meta-analysis in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly ...

“For people with OSA, using CPAP versus not using CPAP can literally be a matter of life or death,” said Carlos Nunez, M.D., Resmed’s Chief Medical Officer. “Decades of research have shown CPAP can ...

Resmed (NYSE: RMD) announced today that it began a comprehensive brand evolution to unify its brand portfolio.

ResMed has launched a rebrand to unify its portfolio and reflect its increasing direct-to-consumer engagement.

ResMed makes continuous positive airway pressure machines (CPAP), which offer a non-invasive treatment option for sleep apnea characterized by brief interruptions of breathing during sleep.

ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst remained upbeat on the "mega trends" driving the CPAP maker. Please watch the ...

And in a show of unusual strength, maker of CPAP breathing devices closed at 236.63, up 1.8% for the day. It did that in a session that saw the Dow Jones Industrial Index plunge 890 points. ResMed ...

The company has launched initiatives including a consumer campaign for CPAP therapy and a physician education campaign to facilitate earlier diagnosis. By 2030, Resmed aims to empower 500 million ...

For 35 years, Resmed has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions. The company’s last major brand update in 2014 marked its shift to ...

CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea, according to a landmark meta-analysis supported by Resmed and published in The Lancet Respiratory Medicine ...

Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of dy ...